Head to Head Comparison: Amneal Pharmaceuticals (NASDAQ:AMRX) & Golden Dragon (OTCMKTS:CPMD)

Golden Dragon (OTCMKTS:CPMD) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Golden Dragon and Amneal Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Golden Dragon	0	0	0	0	0.00
Amneal Pharmaceuticals	0	2	6	0	2.75

Amneal Pharmaceuticals has a consensus price target of $15.00, indicating a potential upside of 15.21%. Given Amneal Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Amneal Pharmaceuticals is more favorable than Golden Dragon.

Insider & Institutional Ownership

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 1.3% of Golden Dragon shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Golden Dragon and Amneal Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Golden Dragon	$1.36 million	1.94	-$11.13 million	($0.01)	-0.39
Amneal Pharmaceuticals	$3.02 billion	1.36	$72.06 million	$0.23	56.61

Amneal Pharmaceuticals has higher revenue and earnings than Golden Dragon. Golden Dragon is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Golden Dragon and Amneal Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Golden Dragon	-816.80%	N/A	-107.71%
Amneal Pharmaceuticals	2.39%	-228.24%	6.91%

Risk and Volatility

Golden Dragon has a beta of 2.49, meaning that its stock price is 149% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.

Summary

Amneal Pharmaceuticals beats Golden Dragon on 11 of the 14 factors compared between the two stocks.

About Golden Dragon

CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.